Trial Profile
A randomized placebo-controlled, dose-finding study of oral besifovir in HBeAg-positive patients with chronic hepatitis B.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Besifovir (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors LG Life Sciences
- 05 Nov 2010 New trial record.